InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (4 ops.)
Insider track record
Board DirectorDisclosed buys
6
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Wiggans Thomas G, Director. Insider active across 4 companies, notably Forma Therapeutics Holdings, Inc.. Aggregated, 14 disclosures have been recorded. Split: 6 buys · 4 sells. Total volume traded: €140k. Activity tracked since 17 June 2021. The latest transaction was filed on 22 September 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Wiggans Thomas G
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
41,000 shares@ US$2.4383.0% of flowVoting Common StockSEC:0001213900-25-091105:0
Canonical exit: 21 Dec 2025 (T+90)
10,000 shares@ US$0.648634.3% of flowVoting Common StockSEC:0001213900-23-091458:0
Canonical exit: 26 Feb 2024 (T+90)
10,000 shares@ US$0.638333.8% of flowVoting Common StockSEC:0001213900-23-089579:0
Canonical exit: 19 Feb 2024 (T+90)
10,000 shares@ US$0.596531.9% of flowVoting Common StockSEC:0001213900-23-088896:0
Canonical exit: 14 Feb 2024 (T+90)
50,000 sharesCommon StockSEC:0001209191-23-047836:0
12,500 shares@ US$1.0934.1% of flowCommon StockSEC:0001209191-22-060154:0
Canonical exit: 5 Mar 2023 (T+90)
25,000 shares@ US$1.0465.9% of flowCommon StockSEC:0001209191-22-059677:0
Canonical exit: 1 Mar 2023 (T+90)
7,250 sharesCommon StockSEC:0000899243-22-033650:0
4,500 shares0Common StockSEC:0000899243-22-021666:0
2,750 shares0Common StockSEC:0000899243-21-025095:0
8,700 sharesCommon StockSEC:0001562180-16-001471:0
300 sharesCommon StockSEC:0001562180-16-001471:1
10,492 sharesCommon StockSEC:0001562180-16-001270:0
508 sharesCommon StockSEC:0001562180-16-001270:1
14 of 14 declarations
About Wiggans Thomas G
Thomas G. Wiggans is Administrateur and has 14 filings in total. Among the 14 sampled filings, all are buys for a total of EUR 139531, with no sells, and they span from 2016-01-06 to 2025-09-24. The recent filings relate to Jasper Therapeutics, Inc. and Pardes Biosciences, INC., with individual amounts of EUR 84424.471369359, EUR 24939.20052562364 and EUR 12921.81346878454 for Pardes Biosciences, INC., and EUR 5918.734507960324, EUR 5831.381428725613 and EUR 5495.375338134178 for Jasper Therapeutics, Inc.
